A detailed history of Zacks Investment Management transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 26,334 shares of PLRX stock, worth $48,454. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,334
Holding current value
$48,454
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025

BUY
$1.16 - $1.69 $30,547 - $44,504
26,334 New
26,334 $30,000

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $89.6M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track Zacks Investment Management Portfolio

Follow Zacks Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Zacks Investment Management with notifications on news.